Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.10.5007

Prediction Value of XRCC 1 Gene Polymorphism on the Survival of Ovarian Cancer Treated by Adjuvant Chemotherapy  

Miao, Jin (Department of Gynecology and Obstetrics, the First Affiliated Hospital of Jinan University)
Zhang, Xian (Department of Gynecology and Obstetrics, the First Affiliated Hospital of Jinan University)
Tang, Qiong-Lan (Department of Pathology, the Sun Yat-sen Memorial Hospital of Sun Yat-sen University)
Wang, Xiao-Yu (Department of Gynecology and Obstetrics, the First Affiliated Hospital of Jinan University)
Kai, Li (Department of Oncology, Chinese Medical Sciences University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.10, 2012 , pp. 5007-5010 More about this Journal
Abstract
Objective: We conducted a prospective study to test the association between three amino acid substitution polymorphismic variants of DNA repair genes, XRCC1 (Arg194Trp), XRCC1(Arg280His) and XRCC1 (Arg399Gln), and clinical outcome of ovarian cancer patients undergoing adjuvant chemotherapy. Methods: 195 patients with primary advanced ovarian cancer and treated by adjuvant chemotherapy were included in our study. All were followed-up from Jan. 2007 to Jan. 2012. Genotyping of XRCC1 polymorphisms was conducted by TaqMan Gene Expression assays. Results: The XRCC1 194 Trp/Trp genotype conferred a significant risk of death from ovarian cancer when compared with Arg/Arg (HR=1.56, 95%CI=1.04-3.15). Similarly, those carrying the XRCC1 399 Gln/Gln genotype had a increased risk of death as compared to the XRCC1 399Arg/Arg genotype with an HR (95% CI) of 1.98 (1.09-3.93). Conclusion: This study is the first to provide evidence that XRCC1 gene polymorphisms would well be useful as surrogate markers of clinical outcome in ovarian cancer cases undergoing adjuvant chemotherapy.
Keywords
Ovarian cancer; XRCC1; adjuvant chemotherapy; polymorphism;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Liu YP, Ling Y, Zhang YP, et al (2011). Predictive values of platinum-rel`1ated gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy. Zhonghua Yi Xue Za Zhi, 91, 256-9.
2 Nazarkina ZK, Khodyreva SN, Marsin S, et al (2007). XRCC1 interactions with base excision repair DNA intermediates. DNA Repair (Amst), 6, 254-64.   DOI
3 Piccart MJ, Lamb H, Vermorken JB, et al (2001). Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol, 12, 1195-203.   DOI
4 Price N (2004). Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin Lung Cancer, 6, 79-82.   DOI
5 Ren S, Zhou S, Zhang L, et al (2010). High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest, 28, 1078-83.   DOI   ScienceOn
6 Savas S, Kim DY, Ahmad MF, et al (2004). Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev, 13, 801-7.
7 Shirota Y, Stoehlmacher J, Brabender J, et al (2001). ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 19, 4298-304.
8 Siddiqui-Jain A, Bliesath J, Macalino D, et al (2012). CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Mol Cancer Ther, 11, 994-1005.   DOI
9 Simon GR, Sharma S, Cantor A, et al (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127, 978-83.   DOI   ScienceOn
10 Stern MC, Siegmund KD, Conti DV, et al (2006). XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev, 15, 2384-90.   DOI
11 Weijl NI, Cleton FJ, Osanto S, et al (1997). Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev, 23, 209-40.   DOI   ScienceOn
12 Williams SD, Blessing JA, Moore DH, et al (1989). Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med, 111, 22-7.   DOI   ScienceOn
13 Zhou W, Gurubhagavatula S, Liu G, et al (2004). Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 10, 4939-43.   DOI
14 Chang-Claude J, Popanda O, et al (2005). Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res, 11, 4802-9.   DOI
15 Allan JM, Smith AG, Wheatley K, et al (2004). Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood, 104, 3872-7.   DOI
16 Brem R, Hall J (2005). XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res, 33, 2512-20.   DOI   ScienceOn
17 Britten RA, Liu D, Tessier A, et al (2000). ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer, 89, 453-7.   DOI
18 Cui Z, Yin Z, Li X, et al (2012). Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC Cancer, 12, 71.   DOI   ScienceOn
19 Harries M, Kaye SB (2001). Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs, 10, 1715-24.   DOI
20 Hirata H, Hinoda Y, Tanaka Y, et al (2007). Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer, 43, 23107.
21 Hogberg T, Glimelius B, Nygren P, et al (2001). A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol, 40, 340-60.   DOI
22 Huang WY, Chow WH, Rothman N, et al (2005). Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis, 26, 1354-9.   DOI   ScienceOn
23 Kiyohara C, Takayama K, Nakanishi Y (2006). Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer, 54, 267-83.   DOI
24 Jakubowska A, Gronwald J, Menkiszak J, et al (2010). BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat, 119, 201-11.   DOI
25 Khrunin AV, Moisseev A, Gorbunova V, et al (2010). Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J, 10, 54-61.   DOI
26 Kim HS, Kim MK, Chung HH, et al (2009). Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol, 113, 264-9.   DOI
27 Krivak TC, Darcy KM, Tian C, et al (2011). Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol, 122, 121-6.   DOI
28 La Torre F, Orlando A, Silipigni A, et al (1997). Increase of oxygen free radicals and their derivatives in chemoand radiation treated neoplasm patients. Minerva Med, 88, 121-6.
29 Liang J, Jiang T, Yao RY, et al (2010). The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol, 66, 493-500.   DOI
30 Liao WY, Shih JY, Chang GC, et al (2012). Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in nonsmall-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol, 7, 973-81.   DOI